Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
Status:
Not yet recruiting
Trial end date:
2030-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomised, controlled, multicentre study to compare the efficacy and
safety between continuous or intermittent extension of adjuvant pyrotinib in invasive
HER2-positive breast cancer.